Microbiology test kit maker TREK Diagnostic Systems has been sold to Thermo Fisher Scientific (NYSE: TMO) for an unspecified amount.
TREK is based in the Cleveland area and also has a United Kingdom location. It had revenue of $34 million last year and employs 150 people. About 40 of those employees are in Cleveland, a Thermo Fisher spokesman said.
The spokesman said the company doesn’t comment on what effect its acquisitions have on job numbers, so it’s unclear if any jobs will be lost as part of the deal. But it sounds as if most TREK employees will be able to escape the axe. “The fact that all the employees are part of the acquisition is a good thing,” the spokesman said.
Redefining Payer Operations: Data-Driven Strategies for the Future of Healthcare
This eBook provides actionable strategies, real-world best practices to help payers stay ahead in a value-based care environment.
TREK was purchased in 2006 by Magellan Biosciences, which, like Thermo Fisher, is based in the Boston area. Magellan held onto TREK for about five years before selling the company to Thermo Fisher, which sells a broad range of lab equipment and analytical instruments.
“‘The range of products manufactured by TREK ideally complements our existing portfolio of microbiological testing technologies,” said Marc Casper, Thermo Fisher’s CEO.
TREK’s Sensitire product line of “susceptibility plates” is used to determine the appropriate drug and dosage levels required to treat bacterial and yeast infections.